T cells engineered with a 4-1BB-ζ CAR targeting CD19 recently produced spectacular efficacy toward refractory leukemia in patients with high tumor burden (Kalos et al., 2011; Grupp et al., 2013). The gene discussed is CD19; the disease is neoplasm.